BACKGROUND: In sub-Saharan Africa, most HIV-infected patients receive antiretroviral therapy (ART) without virological monitoring. Longitudinal data on secondary resistance are rare. METHODS: We conducted a prospective cohort study of HIV-1-infected adults initiating ART in 3 clinics using computerized monitoring systems. Patients had plasma HIV-1 RNA viral load (VL) tests at months 12 (M12) and 24 (M24) after ART initiation and HIV-1 resistance genotype tests if VL was detectable (≥300 copies/mL). RESULTS: Overall, 1573 patients initiated ART with stavudine/zidovudine plus lamivudine plus nevirapine/efavirenz. At M12 and M24, 944 and 844 patients, respectively, remained in active follow-up. Among them, 25% (M12) and 27% (M24) had detectable VLs and 12% (M12) and 19% (M24) had virus resistant to at least 1 antiretroviral drug, accounting for 54% (M12) and 75% (M24) of patients with detectable VLs. Among the resistant strains, 95% (M12) and 97% (M24) were resistant to lamivudine/emtricitabine, efavirenz, and/or nevirapine, the frequency of thymidine analog mutations increased from 8.1% (M12) to 14.7% (M24) and etravirine resistance increased from 13.5% (M12) to 24.5% (M24). CONCLUSIONS: Of the patients with detectable VLs at M24, 25% still did not harbor resistant virus. Preventing mutations from emerging with adherence reinforcement in patients with detectable VLs remains important beyond M24. Switching therapy early in patients with resistance to 3 TC/FTC and/or to nonnucleoside reverse transcriptase inhibitors to prevent extended resistance to nucleoside reverse transcriptase inhibitors and etravirine resistance from occurring is also a major challenge.
BACKGROUND: In sub-Saharan Africa, most HIV-infectedpatients receive antiretroviral therapy (ART) without virological monitoring. Longitudinal data on secondary resistance are rare. METHODS: We conducted a prospective cohort study of HIV-1-infected adults initiating ART in 3 clinics using computerized monitoring systems. Patients had plasma HIV-1 RNA viral load (VL) tests at months 12 (M12) and 24 (M24) after ART initiation and HIV-1 resistance genotype tests if VL was detectable (≥300 copies/mL). RESULTS: Overall, 1573 patients initiated ART with stavudine/zidovudine plus lamivudine plus nevirapine/efavirenz. At M12 and M24, 944 and 844 patients, respectively, remained in active follow-up. Among them, 25% (M12) and 27% (M24) had detectable VLs and 12% (M12) and 19% (M24) had virus resistant to at least 1 antiretroviral drug, accounting for 54% (M12) and 75% (M24) of patients with detectable VLs. Among the resistant strains, 95% (M12) and 97% (M24) were resistant to lamivudine/emtricitabine, efavirenz, and/or nevirapine, the frequency of thymidine analog mutations increased from 8.1% (M12) to 14.7% (M24) and etravirine resistance increased from 13.5% (M12) to 24.5% (M24). CONCLUSIONS: Of the patients with detectable VLs at M24, 25% still did not harbor resistant virus. Preventing mutations from emerging with adherence reinforcement in patients with detectable VLs remains important beyond M24. Switching therapy early in patients with resistance to 3 TC/FTC and/or to nonnucleoside reverse transcriptase inhibitors to prevent extended resistance to nucleoside reverse transcriptase inhibitors and etravirine resistance from occurring is also a major challenge.
Authors: Nellie Wadonda-Kabondo; Bethany L Hedt; Joep J van Oosterhout; Kundai Moyo; Eddie Limbambala; George Bello; Ben Chilima; Erik Schouten; Anthony Harries; Moses Massaquoi; Carol Porter; Ralf Weigel; Mina Hosseinipour; John Aberle-Grasse; Michael R Jordan; Storn Kabuluzi; Diane E Bennett Journal: Clin Infect Dis Date: 2012-05 Impact factor: 9.079
Authors: Raph L Hamers; Kim C E Sigaloff; Annemarie M Wensing; Carole L Wallis; Cissy Kityo; Margaret Siwale; Kishor Mandaliya; Prudence Ive; Mariette E Botes; Maureen Wellington; Akin Osibogun; Wendy S Stevens; Tobias F Rinke de Wit; Rob Schuurman Journal: Clin Infect Dis Date: 2012-04-03 Impact factor: 9.079
Authors: Kim C E Sigaloff; Raph L Hamers; Carole L Wallis; Cissy Kityo; Margaret Siwale; Prudence Ive; Mariette E Botes; Kishor Mandaliya; Maureen Wellington; Akin Osibogun; Wendy S Stevens; Michèle van Vugt; Tobias F Rinke de Wit Journal: J Acquir Immune Defic Syndr Date: 2011-09-01 Impact factor: 3.731
Authors: Diane E Bennett; Michael R Jordan; Silvia Bertagnolio; Steven Y Hong; Giovanni Ravasi; James H McMahon; Ahmed Saadani; Karen F Kelley Journal: Clin Infect Dis Date: 2012-05 Impact factor: 9.079
Authors: Viktor von Wyl; Valentina Cambiano; Michael R Jordan; Silvia Bertagnolio; Alec Miners; Deenan Pillay; Jens Lundgren; Andrew N Phillips Journal: PLoS One Date: 2012-08-08 Impact factor: 3.240
Authors: Bruce R Schackman; David W Haas; Sanghee S Park; X Cynthia Li; Kenneth A Freedberg Journal: Pharmacogenomics Date: 2015-11-26 Impact factor: 2.533
Authors: Charlotte Boullé; Emilande Guichet; Charles Kouanfack; Avelin Aghokeng; Benjamin Onambany; Catherine Massama Ikaka; Emile Ngock; Landry Tsoumsta; Philippe Msellati; Eitel Mpoudi-Ngolé; Martine Peeters; Eric Delaporte; Christian Laurent Journal: Open Forum Infect Dis Date: 2016-12-20 Impact factor: 3.835